VTGN
Vistagen Therapeutics, Inc.
Key Financials
Net Income
$-69685000
↓ 35.5%
Operating Income
$-72126000
↓ 28.9%
Revenue
$-227000
↓ 229.0%
EPS (Diluted)
$-1.83
↓ 9.6%
Total Assets
$48.6M
↓ 42.4%
Shareholders' Equity
$35.5M
↓ 49.5%
Cash & Equivalents
$30.8M
↓ 54.1%
Long-term Debt
$0.00
N/A
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 8-K | 10/9/2026 | View on SEC |
| 8-K | 9/25/2026 | View on SEC |
| 8-K | 9/24/2026 | View on SEC |
| 8-K | 9/22/2026 | View on SEC |
| 8-K | 9/11/2026 | View on SEC |
| SCHEDULE 13G/A | 8/14/2026 | View on SEC |
| SCHEDULE 13G/A | 8/14/2026 | View on SEC |
| 10-Q | 8/14/2026 | View on SEC |
| SCHEDULE 13G/A | 8/14/2026 | View on SEC |
| 8-K | 8/14/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | VTGN |
| Company Name | Vistagen Therapeutics, Inc. |
| CIK | 1411685 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 0331 |
| State of Incorporation | NV |
| Phone | 650-577-3600 |